Wilkin TJ - Search Results

1

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM. Wilkin TJ, et al. J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6. doi: 10.1097/qai.0b013e3181e2cba0. J Acquir Immune Defic Syndr. 2010. PMID: 20672447 Free PMC article. Clinical Trial.

2

Advances in antiretroviral therapy.

Albrecht MA, Wilkin TJ, Coakley EP, Hammer SM. Albrecht MA, et al. Among authors: wilkin tj. Top HIV Med. 2003 May-Jun;11(3):97-127. Top HIV Med. 2003. PMID: 12837969 Review. No abstract available.

3

Antiretroviral Therapy: When and What to Start-- An American Perspective.

Wilkin TJ, Gulick RM. Wilkin TJ, et al. Curr Infect Dis Rep. 2003 Aug;5(4):339-348. doi: 10.1007/s11908-003-0012-z. Curr Infect Dis Rep. 2003. PMID: 12866986

4

Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA.

Sobieszczyk ME, Coakley EP, Wilkin TJ, Hammer SM. Sobieszczyk ME, et al. Among authors: wilkin tj. Top HIV Med. 2004 Mar-Apr;12(1):9-29. Top HIV Med. 2004. PMID: 15111727

5

Antiretroviral therapy: when and what to start-- an American perspective.

Wilkin TJ, Gulick RM. Wilkin TJ, et al. Curr HIV/AIDS Rep. 2004 Jun;1(2):59-67. doi: 10.1007/s11904-004-0009-8. Curr HIV/AIDS Rep. 2004. PMID: 16091224 Review.

6

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team. Swindells S, et al. JAMA. 2006 Aug 16;296(7):806-14. doi: 10.1001/jama.296.7.806. JAMA. 2006. PMID: 16905786 Clinical Trial.

7

Switching antiretroviral therapy: why, when and how.

Wilkin T, Glesby M, Gulick RM. Wilkin T, et al. IAPAC Mon. 2006 Jul;12(7):220-9. IAPAC Mon. 2006. PMID: 17096494 No abstract available.

8

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. Wilkin TJ, et al. Clin Infect Dis. 2007 Feb 15;44(4):591-5. doi: 10.1086/511035. Epub 2007 Jan 17. Clin Infect Dis. 2007. PMID: 17243065

9

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, Saag M, van Baelen B, Lefebvre E; POWER 2 Study Group. Haubrich R, et al. AIDS. 2007 Mar 30;21(6):F11-8. doi: 10.1097/QAD.0b013e3280b07b47. AIDS. 2007. PMID: 17413685 Clinical Trial.

10

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team. Gulick RM, et al. Among authors: wilkin tj. J Infect Dis. 2007 Jul 15;196(2):304-12. doi: 10.1086/518797. Epub 2007 Jun 5. J Infect Dis. 2007. PMID: 17570119 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters